Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 6/20 | 0.76 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.76 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.76 |
| ▸ | GRIK1 | P39086 | 11/20 | 0.53 |
| ▸ | GRIK2 | Q13002 | 11/20 | 0.53 |
| ▸ | GCLC | P48506 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27937270 | 0.86 | SLC1A2 (1.00) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL7770487 | 0.86 | SLC1A2 (1.00) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL71719 | 0.86 | SLC1A2 (1.00) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL30895 | 0.86 | SLC1A2 (1.00) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL5284609 | 0.86 | SLC1A2 (1.00) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL27041452 | 0.84 | SLC1A2 (0.64) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL27467303 | 0.83 | SLC1A2 (0.76) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL5324268 | 0.83 | SLC1A2 (0.76) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| Ethylene Glycol SCHEMBL28153823 | 0.81 | SLC1A1 (0.88) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL751062 | 0.81 | SLC1A2 (0.71) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172832-B2 | Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators | ALLERGAN, INC. (US) | 2019-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172832-B2 | Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators | FPR1, FPR3, FPR2 | SLC1A2 1560/4885SLC1A1 992/4885SLC1A3 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.